share_log

Genocea Biosciences (NASDAQ:GNCA) Receives New Coverage From Analysts at StockNews.com

Genocea Biosciences (NASDAQ:GNCA) Receives New Coverage From Analysts at StockNews.com

基諾西亞生物科學(NASDAQ:GNCA)在 StockNews 上獲得分析師的新報導
Defense World ·  2022/12/23 16:21

Investment analysts at StockNews.com began coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Rating) in a report issued on Friday. The firm set a "sell" rating on the biotechnology company's stock.

股票新聞網的投資分析師開始對股票的報導 基諾西亞生物科學 (納斯達克:GNCA — 獲得評級) 在星期五發布的報告中。該公司對生物技術公司的股票設定了「賣出」評級。

Genocea Biosciences Price Performance

基諾西亞生物科學價格性能

Shares of Genocea Biosciences stock opened at $0.00 on Friday. The company has a fifty day moving average price of $0.01 and a 200 day moving average price of $0.01. The company has a current ratio of 1.35, a quick ratio of 1.35 and a debt-to-equity ratio of 0.24. Genocea Biosciences has a twelve month low of $0.00 and a twelve month high of $1.48. The stock has a market cap of $35,240.40, a price-to-earnings ratio of 0.00 and a beta of 1.61.

基諾西亞生物科學股票的股票上週五以 0.00 美元開盤。該公司的五十天移動平均價格為 0.01 美元,200 日移動平均價格為 0.01 美元。該公司的流動比率為 1.35,快速比率為 1.35,債務與權益比率為 0.24。赫諾西亞生物科學有十二個月低點 $0.00 和十二個月的高點 $1.48。該股票的市值為 35,240.40 美元,價格與收益比為 0.00,測試版為 1.61。

Get
取得
Genocea Biosciences
赫諾西亞生物科學
alerts:
警報:

Genocea Biosciences Company Profile

基諾西亞生物科學公司簡介

(Get Rating)

(取得評分)

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.
Genocea 生物科學公司是一家生物製藥公司,發現並開發新型癌症免疫療法。該公司使用其專有的發現平台 ATLAS,該平台分析每個患者對該患者腫瘤下一代測序所識別的每個靶標或抗原的 CD4+ 和 CD8+ T 細胞免疫反應。

Featured Articles

特色文章

  • Get a free copy of the StockNews.com research report on Genocea Biosciences (GNCA)
  • Your Decision to Buy Palantir May Simply Be a Matter of Time
  • Are Caterpillar and Deere Setting Up to Rally in 2023?
  • Mullen Automotive Gets a Jolt as the I-GO Arrives in Europe
  • Will The Sun Shine On These 3 Large-Cap Solar Stocks In 2023?
  • Lucid Motors Faces a Reality That May Cloud a Bullish Perception
  • 獲取有關基諾西亞生物科學研究報告的免費副本
  • 您購買 Palantir 的決定可能只是時間問題
  • 卡特彼勒和迪爾是否在 2023 年設置集會?
  • 馬倫汽車獲取一個顛簸作為 I-GO 到達歐洲
  • 在 2023 年,陽光會在這 3 個大型股太陽能股上閃耀嗎?
  • 清醒汽車面臨的現實可能會影響看漲的感知

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

接收赫諾西亞生物科學日報的新聞和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Genocea 生物科學和相關公司的最新新聞和分析師評級的簡要每日摘要。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論